Arcadia Biosciences Files 8-K on Shareholder Vote Matters

TL;DR

Arcadia Biosciences (RKDA) is holding a shareholder vote on Dec 19th matters.

AI Summary

Arcadia Biosciences, Inc. filed an 8-K on December 23, 2025, reporting a submission of matters to a vote of security holders as of December 19, 2025. The company, incorporated in Delaware, is headquartered in Dallas, Texas, and operates in the Crude Petroleum & Natural Gas sector.

Why It Matters

This filing indicates that Arcadia Biosciences is proceeding with important decisions requiring shareholder approval, which could impact the company's future direction and operations.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote matter, not indicating immediate financial distress or significant operational changes.

Key Numbers

• 001-37383 — SEC File Number (Identifies the company's filing history with the SEC.)
• 81-0571538 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Arcadia Biosciences, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Dallas, Texas (location) — Principal Executive Offices
• 214-974-8921 (phone_number) — Registrant's Telephone Number
• December 19, 2025 (date) — Date of earliest event reported
• December 23, 2025 (date) — Date of Report

FAQ

Filing Documents

• rkda-20251219.htm (8-K) — 72KB
• 0001193125-25-331009.txt ( ) — 176KB
• rkda-20251219.xsd (EX-101.SCH) — 24KB
• rkda-20251219_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the annual meeting of stockholders of Arcadia Biosciences, Inc. (the "Company") held on December 19, 2025 (the "Annual Meeting"), stockholders holding and entitled to vote 703,677 shares of common stock of the Company, or approximately 51% of the total outstanding shares of common stock on the record date for the Annual Meeting, were present in person or by proxy. At the Annual Meeting, the stockholders voted on the following three proposals, each of which is described in detail in the definitive proxy statement filed with the Securities and Exchange Commission on November 19, 2025. The final results for each of the matters considered at the Annual Meeting were as follows: PROPOSAL I: Election of Directors The director nominees were elected to serve as a Class I directors until the Company's annual meeting of stockholders in 2028, or until their successors are duly elected and qualified, or their earlier resignation, death, or removal. Due to plurality election, votes could only be cast in favor of or withheld from the nominees and thus votes against were not applicable. The results of the election were as follows: DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Albert Bolles, Ph.D. 79,563 64,287 559,827 Kevin Comcowich 78,305 65,545 559,827 Thomas J. Schaefer 79,563 64,287 559,827 PROPOSAL II: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers by the votes set forth in the table below: FOR AGAINST ABSTAIN BROKER NON-VOTES 72,445 70,865 540 559,827 PROPOSAL III: Ratification of Selection of Independent Registered Public Accountants The appointment of Deloitte & Touche LLP as the Company's independent registered public accountants for the year ending December 31, 2025, was ratified by the affirmative votes of the stockholders. The

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCADIA BIOSCIENCES, INC. Date: December 23, 2025 By: /s/ THOMAS J. SCHAEFER Thomas J. Schaefer, Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR